LP
CRDF icon

LMR Partners’s Cardiff Oncology CRDF Stock Holding History

LMR Partners’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,101
Closed -$70K – 1135
2024
Q1 		$70K Buy
+13,101
New +$34.8K ﹤0.01% 957
2022
Q4 		– Sell
-13,584
Closed -$21K – 1133
2022
Q3 		$21K Hold
13,584
– – ﹤0.01% 1158
2022
Q2 		$30K Buy
+13,584
New +$22.8K ﹤0.01% 1204
2021
Q2 		– Sell
-23,332
Closed -$216K – 1161
2021
Q1 		$216K Buy
+23,332
New +$283K 0.01% 784
2017
Q3 		– Sell
-1,666
Closed -$151K – 360
2017
Q2 		$151K Buy
+1,666
New +$107K 0.01% 548

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's CRDF Position: Q2 2024 in Review

LMR Partners sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 13,101 shares — an estimated $70K sold.

LMR Partners first reported a position in CRDF in Q2 2017 and held it in 5 quarters. The position peaked at $216K in Q1 2021. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

  • LMR Partners reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 13,101 Cardiff Oncology shares in Q2 2024, an estimated $70K.
  • LMR Partners first reported a position in Cardiff Oncology in Q2 2017 and held it in 5 quarters.
  • LMR Partners's Cardiff Oncology position peaked at $216K in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.